Ashwani Verma
Stock Analyst at UBS
(4.09)
# 470
Out of 5,245 analysts
114
Total ratings
59.76%
Success rate
10.22%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Upgrades: Buy | $188 → $307 | $239.83 | +28.01% | 8 | May 19, 2026 | |
| CORT Corcept Therapeutics | Upgrades: Buy | $44 → $72 | $60.22 | +19.56% | 2 | May 13, 2026 | |
| ALKS Alkermes | Maintains: Buy | $42 → $48 | $36.80 | +30.43% | 6 | May 6, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $36 → $42 | $34.07 | +23.28% | 11 | Apr 30, 2026 | |
| RPRX Royalty Pharma | Maintains: Buy | $51 → $57 | $54.50 | +4.59% | 5 | Apr 21, 2026 | |
| AMRX Amneal Pharmaceuticals | Initiates: Buy | $19 | $12.42 | +52.98% | 1 | Apr 17, 2026 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $251 → $259 | $235.97 | +9.76% | 8 | Apr 10, 2026 | |
| INCY Incyte | Maintains: Neutral | $104 → $94 | $97.16 | -3.25% | 3 | Mar 25, 2026 | |
| ALVO Alvotech | Maintains: Buy | $10 → $6 | $3.34 | +79.64% | 2 | Mar 24, 2026 | |
| CYTK Cytokinetics | Maintains: Neutral | $61 → $69 | $76.94 | -10.32% | 6 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $655 → $705 | $568.43 | +24.03% | 12 | Mar 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $43 → $46 | $30.15 | +52.57% | 4 | Feb 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $188 → $178 | $156.70 | +13.59% | 11 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $223 → $215 | $106.24 | +102.37% | 1 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 → $40 | $21.10 | +89.57% | 9 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $48 | $29.37 | +63.43% | 4 | Dec 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $26 → $11 | $9.45 | +16.40% | 5 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $195 → $220 | $215.70 | +1.99% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $40 | $50.15 | -20.24% | 5 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $34.15 | -47.29% | 1 | Jul 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.5 → $1.05 | $1.61 | -34.78% | 5 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $377.57 | -98.15% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $16.65 | -27.93% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $1.07 | +1,301.87% | 1 | Oct 11, 2022 |
Jazz Pharmaceuticals
May 19, 2026
Upgrades: Buy
Price Target: $188 → $307
Current: $239.83
Upside: +28.01%
Corcept Therapeutics
May 13, 2026
Upgrades: Buy
Price Target: $44 → $72
Current: $60.22
Upside: +19.56%
Alkermes
May 6, 2026
Maintains: Buy
Price Target: $42 → $48
Current: $36.80
Upside: +30.43%
Teva Pharmaceutical Industries
Apr 30, 2026
Maintains: Buy
Price Target: $36 → $42
Current: $34.07
Upside: +23.28%
Royalty Pharma
Apr 21, 2026
Maintains: Buy
Price Target: $51 → $57
Current: $54.50
Upside: +4.59%
Amneal Pharmaceuticals
Apr 17, 2026
Initiates: Buy
Price Target: $19
Current: $12.42
Upside: +52.98%
Axsome Therapeutics
Apr 10, 2026
Maintains: Buy
Price Target: $251 → $259
Current: $235.97
Upside: +9.76%
Incyte
Mar 25, 2026
Maintains: Neutral
Price Target: $104 → $94
Current: $97.16
Upside: -3.25%
Alvotech
Mar 24, 2026
Maintains: Buy
Price Target: $10 → $6
Current: $3.34
Upside: +79.64%
Cytokinetics
Mar 6, 2026
Maintains: Neutral
Price Target: $61 → $69
Current: $76.94
Upside: -10.32%
Mar 5, 2026
Maintains: Buy
Price Target: $655 → $705
Current: $568.43
Upside: +24.03%
Feb 11, 2026
Downgrades: Neutral
Price Target: $43 → $46
Current: $30.15
Upside: +52.57%
Jan 23, 2026
Maintains: Buy
Price Target: $188 → $178
Current: $156.70
Upside: +13.59%
Jan 6, 2026
Maintains: Buy
Price Target: $223 → $215
Current: $106.24
Upside: +102.37%
Jan 6, 2026
Maintains: Buy
Price Target: $35 → $40
Current: $21.10
Upside: +89.57%
Dec 8, 2025
Maintains: Buy
Price Target: $54 → $48
Current: $29.37
Upside: +63.43%
Nov 26, 2025
Downgrades: Neutral
Price Target: $26 → $11
Current: $9.45
Upside: +16.40%
Nov 7, 2025
Maintains: Neutral
Price Target: $195 → $220
Current: $215.70
Upside: +1.99%
Nov 6, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $50.15
Upside: -20.24%
Jul 28, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $34.15
Upside: -47.29%
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $1.61
Upside: -34.78%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $377.57
Upside: -98.15%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $16.65
Upside: -27.93%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $1.07
Upside: +1,301.87%